| Literature DB >> 26327531 |
Amy McGowan1, Giuliana Silvestri2, Evelyn Moore3, Vittorio Silvestri3, Christopher C Patterson1, Alexander P Maxwell1, Gareth J McKay1.
Abstract
BACKGROUND: Chronic kidney disease (CKD) and hypertension are global public health problems associated with considerable morbidity, premature mortality and attendant healthcare costs. Previous studies have highlighted that non-invasive examination of the retinal microcirculation can detect microvascular pathology that is associated with systemic disorders of the circulatory system such as hypertension. We examined the associations between retinal vessel caliber (RVC) and fractal dimension (DF), with both hypertension and CKD in elderly Irish nuns.Entities:
Mesh:
Year: 2015 PMID: 26327531 PMCID: PMC4556713 DOI: 10.1371/journal.pone.0136434
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Retinal vascular calibre measurement.
Retinal arteriolar and venular calibers were summarized as central retinal arteriolar (CRAE) and the central retinal venular (CRVE) equivalent respectively from digital retinal fundus images using the Interactive Vessel Analysis software (IVAN, University of Wisconsin, US). Arterioles are in red and venules are in blue.
Fig 2Retinal vascular fractal dimension measurement.
The upper image illustrates a retinal fundus image and skeletonized line tracing of an eye with a low fractal dimension and less complex (more rarefied) branching pattern; the lower retinal fundus image and skeletonized line tracing illustrates a higher fractal dimension and a more complex (dense) branching pattern.
Summary statistics of participants included for retinal vessel assessment by hypertension status.
| Characteristic | With hypertension, n = 667 | No hypertension, n = 455 |
|
|---|---|---|---|
| Age, years Mean (SD) | 77.8 (7.7) | 74.0 (8.0) |
|
| Body Mass Index, kg/m2 Mean (SD) | 25.1 (5.2) | 23.9 (4.8) |
|
| MABP, mmHg Mean (SD) | 96.8 (9.5) | 86.0 (8.0) |
|
| Ever smoked, n (%) | 29 (4) | 20 (4) | 0.97 |
| Any alcohol consumption | 44 (8) | 33 (9) | 0.57 |
| Ischemic Heart Disease, n (%) | 101 (15) | 19 (4) |
|
| Cerebrovascular accident, n (%) | 25 (4) | 11 (2) | 0.22 |
| Diabetes mellitus, n (%) | 24 (4) | 10 (2) | 0.18 |
| Chronic kidney disease, n (%) | 410 (65) | 213 (50) |
|
| ACE inhibitors | 121 (18) | 13 (3) |
|
| Aspirin | 281 (42) | 88 (19) |
|
| Beta blockers | 167 (25) | 25 (5) |
|
| Calcium channel blockers | 126 (19) | 16 (4) |
|
| Corticosteroids | 34 (5) | 28 (6) | 0.45 |
| Diuretics | 208 (31) | 32 (7) |
|
| NSAIDs | 29 (4) | 24 (5) | 0.47 |
| Statins | 303 (45) | 142 (31) |
|
| Central retinal arteriolar equivalent, μm (SD) | 118.9 (12.4) | 122.5 (12.5) |
|
| Central retinal venular equivalent, μm (SD) | 168.1 (18.2) | 170.3 (18.5) |
|
| Fractal Dimension, D | 1.413 (0.062) | 1.427 (0.062) |
|
SD: standard deviation; MABP: mean arterial blood pressure (one third of the systolic blood pressure plus two thirds of the diastolic blood pressure); ACE: angiotensin converting enzyme; NSAIDs: nonsteroidal anti-inflammatory drugs.
*Medications with a frequency >5%.
✝Data on alcohol consumption was only available in 941 participants who completed a food frequency questionnaire.
Summary statistics of participants included for retinal vessel assessment by CKD status.
| Characteristic | With CKD, n = 623 | No CKD, n = 437 |
|
|---|---|---|---|
| Mean Age, years (SD) | 78.3 (7.6) | 73.8 (7.9) |
|
| Mean Body Mass Index, kg/m2 (SD) | 24.9 (5.2) | 24.2 (4.8) |
|
| Mean MABP, mmHg (SD) | 92.9 (9.8) | 91.5 (11) |
|
| Ever smoked, n (%) | 24 (4) | 22 (5) | 0.35 |
| Any alcohol consumption | 41 (7) | 33 (9) | 0.34 |
| Ischemic Heart Disease, n (%) | 81 (13) | 33 (8) |
|
| Cerebrovascular accident, n (%) | 24 (4) | 11 (3) | 0.23 |
| Diabetes mellitus, n (%) | 26 (4) | 8 (2) | 0.03 |
| Hypertension, n (%) | 410 (66) | 221 (51) |
|
| ACE inhibitors | 90 (14) | 35 (8) |
|
| Aspirin | 247 (40) | 103 (24) |
|
| Beta blockers | 124 (20) | 58 (13) |
|
| Calcium channel blockers | 84 (13) | 51 (12) | 0.38 |
| Corticosteroids | 28 (4) | 29 (7) | 0.13 |
| Diuretics | 156 (25) | 64 (15) |
|
| NSAIDs | 23 (4) | 26 (6) | 0.09 |
| Statins | 274 (44) | 146 (33) |
|
| Central retinal arteriolar equivalent, μm (SD) | 120.0 (12.6) | 120.8 (12.4) | 0.27 |
| Central retinal venular equivalent, μm (SD) | 168.9 (18.7) | 169.2 (17.9) | 0.81 |
| Fractal Dimension, D | 1.417 (0.061) | 1.423 (0.063) | 0.16 |
SD: standard deviation; MABP: mean arterial blood pressure (one third of the systolic blood pressure plus two thirds of the diastolic blood pressure); ACE: angiotensin converting enzyme; NSAIDs: nonsteroidal anti-inflammatory drugs.
*Medications with a frequency >5%.
✝Data on alcohol consumption was only available in 941 participants who completed a food frequency questionnaire.
Difference in mean retinal vascular caliber and fractal dimension between those with and without hypertension and CKD before and after adjustment for confounders.
| Dependent variable | Model 1 | Model 2 | Model 3 | Model 4 | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| CRAE | -3.62 (-5.11, -2.14) |
| -3.12 (-4.68, -1.56) |
| -3.06 (-4.78, -1.35) |
| -2.16 (-3.51, -0.81) |
|
| CRVE | -2.26 (-4.44, -0.08) |
| -1.54 (-3.82, 0.73) | 0.18 | -2.13 (-4.63, 0.37) | 0.094 | 0.63 (-1.34, 2.61) | 0.53 |
| Fractal Dimension | -0.014 (-0.021, -0.007) |
| -0.006 (-0.013, 0.002) | 0.14 | -0.006 (-0.014, 0.003) | 0.17 | NA | |
|
|
|
|
|
|
|
|
| |
| CRAE | -0.87 (-2.41, 0.67) | 0.26 | 0.81 (-0.74, 2.37) | 0.31 | 0.72 (-0.86, 2.30) | 0.37 | -0.12 (-1.37, 1.12) | 0.85 |
| CRVE | -0.27 (-2.52, 1.98) | 0.81 | 2.07 (-0.20, 4.34) | 0.07 | 1.98 (-0.32, 4.28) | 0.09 | 1.33 (-0.47, 3.14) | 0.15 |
| Fractal Dimension | -0.005 (-0.013, 0.002) | 0.16 | 0.005 (-0.002, 0.013) | 0.19 | 0.005 (-0.003, 0.012) | 0.23 | NA |
Model 1- Unadjusted; model 2: adjusted for age, BMI, smoking status, alcohol, refraction, diabetes mellitus, chronic kidney disease or hypertension, ischemic heart disease, and cerebrovascular accident; model 3: adjusted for model 2 covariates and medications used at a frequency >5% within the cohort (angiotensin converting enzyme inhibitors, aspirin, beta blockers, calcium channel blockers, corticosteroids, diuretics, nonsteroidal anti-inflammatory drugs and statins).; model 4: adjusted for model 3 covariates and fellow vessel caliber. CRAE: central retinal arteriolar equivalent; CRVE: central retinal venular equivalent; 95% CI: 95% confidence intervals. NA: not applicable.